DexCom, Inc. (DXCM) Return on Equity (ROE): 31.47%
Is DexCom, Inc.’s return on equity (ROE) high or low?
DexCom, Inc.'s return on equity (ROE) of 31.47% is 37% above its 5-year average of 22.95%, near the high end of its 5-year range (10.62%–30.46%).
The return on equity (ROE) for DexCom, Inc. (DXCM) is 31.47% as of Wednesday, June 10, 2026. It is above its 12-month average by 8.78% (28.93%).
DXCM Return on Equity (ROE) Chart
DXCM Average Return on Equity (ROE) Chart
DXCM Current vs Average Return on Equity (ROE) Chart
DXCM Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
31.47%
RETURN ON EQUITY (ROE) AVG TTM
28.93%
RETURN ON EQUITY (ROE) AVG 3Y
25.01%
RETURN ON EQUITY (ROE) AVG 5Y
22.95%
RETURN ON EQUITY (ROE) AVG 10Y
6.26%
RETURN ON EQUITY (ROE) AVG 15Y
-11.66%
RETURN ON EQUITY (ROE) AVG 20Y
-19.14%
CURRENT VS TTM AVG
+8.78%
CURRENT VS 3Y AVG
+25.82%
CURRENT VS 5Y AVG
+37.13%
CURRENT VS 10Y AVG
+402.72%
CURRENT VS 15Y AVG
+369.84%
CURRENT VS 20Y AVG
+264.38%
DXCM Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.24B | 31.47% | 28.93% | 25.01% | 22.95% |
| Biogen Inc. (BIIB) | $29.00B | 7.36% | 8.42% | 11.86% | 16.52% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 22.26% | 21.77% | 21.17% | 17.55% |
| Medline Inc. (MDLN) | $30.90B | 8.55% | 9.02% | 4.86% | 4.86% |
| Veeva Systems Inc. (VEEV) | $26.73B | 12.89% | 12.42% | 12.32% | 13.45% |
| Centene Corporation (CNC) | $31.94B | -30.07% | -10.46% | -1.37% | 1.10% |
| Zoetis Inc. (ZTS) | $34.20B | 81.75% | 66.19% | 56.82% | 52.60% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| BioNTech SE (BNTX) | $21.81B | -6.79% | -4.55% | 10.63% | 21.70% |
Return Analysis
ROE
31.5%
ROA
14.0%
DexCom, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for DexCom, Inc. (DXCM)?
- The return on equity (ROE) for DXCM stock is 31.47%.
- Is DexCom, Inc.'s return on equity (ROE) high or low?
- DexCom, Inc.'s return on equity (ROE) of 31.47% is 37% above its 5-year average of 22.95%, near the high end of its 5-year range (10.62%–30.46%).
- What is the TTM average return on equity (ROE) for DexCom, Inc. (DXCM)?
- The TTM average return on equity (ROE) for DXCM stock is 28.93%.
- What is the 3Y average return on equity (ROE) for DexCom, Inc. (DXCM)?
- The 3Y average return on equity (ROE) for DXCM stock is 25.01%.
- What is the 5Y average return on equity (ROE) for DexCom, Inc. (DXCM)?
- The 5Y average return on equity (ROE) for DXCM stock is 22.95%.
- What is the 10Y average return on equity (ROE) for DexCom, Inc. (DXCM)?
- The 10Y average return on equity (ROE) for DXCM stock is 6.26%.
- What is the 15Y average return on equity (ROE) for DexCom, Inc. (DXCM)?
- The 15Y average return on equity (ROE) for DXCM stock is -11.66%.
- What is the 20Y average return on equity (ROE) for DexCom, Inc. (DXCM)?
- The 20Y average return on equity (ROE) for DXCM stock is -19.14%.
DexCom, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 30.46% |
| 2024-12-31 | 27.40% |
| 2023-12-31 | 26.18% |
| 2022-12-31 | 16.01% |
| 2021-12-31 | 10.62% |
| 2020-12-31 | 27.02% |
| 2019-12-31 | 11.45% |
| 2018-12-31 | -19.16% |
| 2017-12-31 | -11.97% |
| 2016-12-31 | -23.11% |
| 2015-12-31 | -26.04% |
| 2014-12-31 | -15.98% |
| 2013-12-31 | -35.43% |
| 2012-12-31 | -70.78% |
| 2011-12-31 | -42.82% |
| 2010-12-31 | -90.45% |
| 2009-12-31 | 290.18% |
| 2008-12-31 | 283.46% |
| 2007-12-31 | -644.81% |
| 2006-12-31 | -82.00% |
| 2005-12-31 | -62.27% |
| 2004-12-31 | 28.28% |
| 2003-12-31 | 30.41% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | 70.25% |
| 2000-12-31 | 124.26% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach